在头骨底部脑膜大脑内细胞中治疗异常性内高血压的管理算法
Mihika Thapliyal1, Roger Murayi2, Amy S Nowacki1,3
11Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland.
Journal of neurosurgery
|September 27, 2024
概括
在骨底部手术后,针对异常性内高血压 (IIH) 的算法显示复发率低 (3.8%) 和选择性转移 (15.0%). 显著的压力变化表明在侵入性IIH治疗之前需要仔细监测.
科学领域:
- 神经外科 神经外科
- 神经学 神经学
- 眼科医生 眼科 眼科
背景情况:
- 在头骨底部脑膜大脑细胞修复后自发性脑脊液 (sCSF) 泄漏可能导致异常性脑内高血压 (IIH).
- 需要有效的管理算法来指导治疗决策并优化患者的治疗结果.
研究的目的:
- 评估IIH的诊断和管理算法的有效性,在头骨底膜脑瘤修复后的sCSF泄漏患者中.
- 为了评估复发率,移位率和脑脊液 (CSF) 压力动态.
主要方法:
- 对80名因头骨底部sCSF泄漏而手术治疗的患者的回顾性审查 (2014-2021年).
- 术内开口压力 (OP) 测量指导算法应用:高风险 (OP ≥30厘米H2O) 的腹腔关 (VPS),中等风险 (OP = 20-29厘米H2O) 的乙胺和腰部穿刺 (LP),低风险 (OP <20厘米H2O) 的LP.
主要成果:
- 总体VPS泄漏率为15.0%,急性和远程经常性泄漏率分别为3.8%.
- 平均手术内和手术后的OP是相似的 (23.3vs23.0cmH2O,p=0.82),具有显著的个体内变化.
- 26.0%的患者转移到高风险类别,而36.0%的患者转移到低风险类别,基于术后的OP.
结论:
- 一个直接的脑膜大脑细胞修复和选择性的位算法实现了低的CSF泄漏复发率.
- 个体内CSF压力变化凸显了在最终IIH治疗之前需要连续LP的需要.
- 需要进一步的研究,以确定最佳的IIH管理策略在这个患者队列.
相关概念视频
Angle Closure Glaucoma: Treatment
448
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
448
Open Angle Glaucoma: Treatment
403
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
403


